IPOScanner helps investors track upcoming, live and past IPOs in one place with GMP, subscription, allotment status and listing performance insights.
About IPO Scanner
IPOScanner is built for investors who want a clear view of every IPO opportunity in one place. From upcoming issues to live subscription data, allotment updates and listing performance, we bring together the key details you need to track the primary market.
Our tools are designed to be simple, fast and investor-friendly so you can focus on evaluating businesses instead of opening multiple tabs and websites for basic information.
Details of client bank account
For any query / feedback / clarifications, email at
[email protected].
Please read all offer documents and risk disclosures carefully before investing. IPOScanner does not provide investment advice and information on this site should not be treated as a recommendation to apply for any IPO.
© 2026 IPO Scanner. All rights reserved.
Want to stay updated?Subscribe to our newsletter
Scribe Therapeutics Inc.
Scribe Therapeutics is a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies designed to extend healthy lifespan through disease prevention and durable therapeutic intervention.
While current genetic medicines are largely limited to rare disorders, we are engineering our technologies for use in common diseases affecting millions.
By targeting prevalent diseases with significant unmet need and high clinical burden, we aim to usher in a new era of broadly scalable, transformative, and preventative genetic medicines.
Ticker, listing venue and issuer profile
Pricing terms and IPO milestones
Historical financial performance
Official documents from SEC EDGAR
| Form | Filing Date | Document |
|---|---|---|
| S-1 | Jul 2, 2026 | General form for registration of securities under the Securities Act of 1933 |
| DRS/A | Jun 12, 2026 | [Amend] [Cover] Draft Registration Statement |
| DRS/A | Mar 6, 2026 | [Amend] [Cover] Draft Registration Statement |
| DRS | Jan 9, 2026 | [Cover] Draft Registration Statement |
| D | Apr 2, 2021 | Notice of Exempt Offering of Securities |
Contact and headquarters details
Key executives and officers
Benjamin L. Oakes, Ph.D.
President, Chief Executive Officer and Director
Svetlana Lucas, Ph.D.
Chief Business Officer
David L. Parrot, M.B.A.
Chief Financial Officer
James Watson, M.B.A.
Director
Behzad Aghazadeh, Ph.D.
Director
Carl L. Gordon, Ph.D., CFA
Director

Sector
Healthcare
Filed
Jul 02, 2026